首页> 外文期刊>Multiple Sclerosis International >Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials
【24h】

Outcome Measures in Relapsing-Remitting Multiple Sclerosis: Capturing Disability and Disease Progression in Clinical Trials

机译:复发-缓解型多发性硬化的结果指标:在临床试验中捕获残疾和疾病进展

获取原文
           

摘要

Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease that manifests as acute relapses and progressive disability. As a primary endpoint for clinical trials in MS, disability is difficult to both characterize and measure. Furthermore, the recovery from relapses and the rate of disability vary considerably among patients. Given these challenges, investigators have developed and studied the performance of various outcome measures and surrogate endpoints in MS clinical trials. This review defines the outcome measures and surrogate endpoints used to date in MS clinical trials and presents challenges in the design of both adult and pediatric trials.
机译:多发性硬化症(MS)是一种慢性炎症和神经退行性疾病,表现为急性复发和进行性残疾。作为MS临床试验的主要终点,残疾既难以表征也无法测量。此外,患者的复发恢复和残疾率差异很大。面对这些挑战,研究人员已经开发和研究了各种结果测量的性能以及MS临床试验中的替代终点。这篇综述定义了迄今为止在MS临床试验中使用的结局指标和替代终点,并提出了成人和儿童试验设计中的挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号